The Effect of Orally Administered Extracts of Chokeberry, Kamchatka Berry and Blueberry on the Condition of the Eye.

February 3, 2026 updated by: Dorota Szumny, Wroclaw Medical University

Wpływ Podawanego Doustnie Ekstraktu z Aronii, Jagody Kamczackiej Oraz Czarnej Jagody na Stan narządu Wzroku.

This study evaluated whether a standardized berry-extract dietary supplement (AKB; Aronia melanocarpa, Lonicera caerulea, Vaccinium myrtillus) improves visual function in adults with presbyopia. In a randomized, double-blind, placebo-controlled two-period crossover design, participants received AKB 400 mg twice daily and placebo for 6 weeks each, separated by a 5-week washout. Visual function and retinal/neuronal measures were assessed with contrast sensitivity testing, visual fields, VEP, and OCT/AngioOCT. Serum biomarkers related to lens and retinal physiology were also measured.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Participants were randomized to one of two sequences (AKB→placebo or placebo→AKB). Each treatment period lasted 6 weeks, separated by a 5-week washout. Ophthalmological assessments were performed at baseline and during the final week of each treatment period. The primary analysis compared within-participant changes after AKB versus placebo.

Study Type

Interventional

Enrollment (Actual)

27

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Poland
      • Wroclaw, Poland, 50-367
        • Wroclaw Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Age ≥ 50 years.

Clinical diagnosis of presbyopia.

Best-corrected visual acuity (BCVA) ≥ 20/40.

Spherical refraction between -3.0 and +3.0 diopters (D).

Cylinder correction ≤ ±3.0 D.

Exclusion Criteria:

Age < 50 years.

History of ocular surgery within 12 months prior to enrollment.

Presence of ocular diseases/conditions that may affect outcomes, including:

Macular degeneration

Diabetic retinopathy

Retinal vein occlusion

Glaucoma

Other significant acquired or hereditary eye conditions

Neurological disorders affecting visual fields.

Refractive error outside eligibility limits:

Spherical refraction < -3.0 D or > +3.0 D

Cylinder correction > ±3.0 D

Systemic conditions that may influence optic nerve head perfusion, including:

Hypotension

Severe circulatory failure

Vascular endothelial disorders

Gastrointestinal conditions, including:

Hyperacidity

Peptic ulcer disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention 1: Dietary Supplement: AKB
dose: 400 mg capsule, 1 capsule BID (2×/d) throug 6 weeks
Dietary supplement: AKB
Standardized berry extract (Aronia melanocarpa, Lonicera caerulea, Vaccinium myrtillus), 400 mg capsule, BID, 6 weeks
Placebo Comparator: Intervention 2: Placebo
maltodextrin + natural caramel colouring, BID, 6 weeks
Other: Placebo
Matching placebo capsules (maltodextrin + colouring), BID, 6 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in visual field (automated perimetry)
Time Frame: Baseline and Week 6.
Change from baseline in visual field mean deviation (MD, dB) measured by standard automated perimetry measured by Humphrey Field Analyzer.
Baseline and Week 6.
Change in PVEP P100 latency (pattern size 1.0)
Time Frame: Baseline and Week 6.
Change from baseline to Week 6 in PVEP P100 latency (ms) measured by pattern-reversal VEP (pattern size 1.0).
Baseline and Week 6.
Change in PVEP P100 amplitude (pattern size 1.0)
Time Frame: Baseline and Week 6.
Change from baseline to Week 6 in PVEP P100 amplitude (µV) measured by pattern-reversal VEP (pattern size 1.0).
Baseline and Week 6.
Change in PVEP P100 latency (pattern size 0.3)
Time Frame: Baseline and Week 6.
Change from baseline to Week 6 in PVEP P100 latency (ms) measured by pattern-reversal VEP (pattern size 0.3).
Baseline and Week 6.
Change in PVEP P100 amplitude (pattern size 0.3)
Time Frame: Baseline and Week 6.
Change from baseline to Week 6 in PVEP P100 amplitude (µV) measured by pattern-reversal VEP (pattern size 0.3).
Baseline and Week 6.
Change in OCT / OCT-angiography parameters
Time Frame: Baseline and Week 6.
Change from baseline in RNFL thickness (µm) measured by spectral-domain OCT.
Baseline and Week 6.
Change in OCT / OCT-angiography parameters
Time Frame: Baseline and Week 6.
Change from baseline in central macular thickness (µm) measured by spectral-domain OCT.
Baseline and Week 6.
Change in OCT / OCT-angiography parameters
Time Frame: Baseline and Week 6.
Change from baseline in GCC thickness (µm) measured by spectral-domain OCT.
Baseline and Week 6.
Change in OCT / OCT-angiography parameters
Time Frame: Baseline and Week 6.
Change from baseline in retinal vessel density (%) measured by OCT-angiography.
Baseline and Week 6.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in serum CRYAA concentration
Time Frame: One month.
Change from baseline in serum CRYAA concentration measured by ELISA (ng/mL).
One month.
Change in serum CRYAB concentration
Time Frame: one month
Change from baseline in serum CRYAB concentration measured by ELISA (ng/mL).
one month
Change in serum TRPV4 level
Time Frame: one month
Change from baseline in serum TRPV4 level measured by ELISA (ng/mL).
one month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wroclaw Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 3, 2022

Primary Completion (Actual)

March 7, 2023

Study Completion (Actual)

August 15, 2025

Study Registration Dates

First Submitted

January 14, 2026

First Submitted That Met QC Criteria

January 25, 2026

First Posted (Actual)

February 3, 2026

Study Record Updates

Last Update Posted (Actual)

February 6, 2026

Last Update Submitted That Met QC Criteria

February 3, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KB 672/2022, KB 258/2025
  • SUBZ.A080.22.076 and Subz.A080 (Other Grant/Funding Number: Wroclaw Medical University)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Presbyopia

Clinical Trials on AKB

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe